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Angiosarcoma (AS) is a highly aggressive vascular tumor that spreads widely throughout the skin. Since
AS tends to recur locally and metastasize early, an additional intensive therapy is necessary. In this report,
we describe an 83-year-old man with recurrent AS that metastasized to the right external auditory
meatus, who achieved complete remission with CyberKnife and weekly administration of bisphospho-
nate risedronate sodium. Results of the present study might suggest the novel possibility of using
CyberKnife with weekly administration of bisphosphonate risedronate sodium for the treatment of
inoperable metastatic AS.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Angiosarcoma (AS) is a highly aggressive type of vascular tumor
that spreads widely throughout the skin, recurring locally and
metastasizing early.1 Standard treatment with resection and adju-
vant radiotherapy results in local control in approximately 50% of
patients at 1 year and a median survival of approximately 8
months.1e3 Therefore, further intensive therapy is necessary for the
treatment of AS. We previously reported that immunosuppressive
cells, such as tumor-associated macrophages and regulatory T cells,
were dominant in the lesional skin of AS and that tumor-associated
macrophages might be one of the substantial targets for supportive
therapy when used with bisphosphonate (BP) risedronate sodium
for AS.4,5 In this report, we describe a case of recurrent AS that
metastasized to the right external auditory meatus, which wasy have no ﬁnancial or non-
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cal Association. Published by Elsevsuccessfully treated with CyberKnife and weekly administration of
BP risedronate sodium.Case Report
An 83-year-old man consulted us with a symptomatic red nodule
on his scalp. On his initial visit, physical examination revealed a
red, easy-to-bleed, dome-shaped nodule, 30 mm in diameter, on
his forehead (Figure 1A). Histologically, irregular anastomosing
vascular channels lined by single layers of enlarged endothelial
cells existed between collagen bundles, with dense inﬁltration of
lymphocytes (Figure 1B). Immunohistochemical staining revealed
that these enlarged endothelial-like cells were strongly positive
for CD31 and MMP-9 (Figure 1C), and negative for CD34, AE1/AE3,
and Factor VIII. From the above ﬁndings, we diagnosed this case as
MMP-9 expressing cutaneous AS. We resected the tumor with a
1 cm surgical margin. After surgical treatment, we administered
radiation therapy (60 Gy in 30 fractions) to the scalp. Then, we
administered paclitaxel monthly at 80 mg/m2 body surface area
intravenously. After 3 months of using paclitaxel, we stopped the
administration because of arrhythmia. One year later, purpura was
extended around the engrafted skin, which histologically revealedier Taiwan LLC. All rights reserved.
Figure 1 (A) A red, easy-to-bleed, dome-shaped nodule, 30 mm in diameter, on the
forehead. (B) Irregular anastomosing vascular channels lined by single layers of
enlarged endothelial cells existing between collagen bundles, with dense inﬁltration of
lymphocytes. (C) Parafﬁn-embedded tissue sample was deparafﬁnized and stained
with anti-MMP-9Ab. Section was developed with 3,30-diaminobenzidine tetrahydro-
chloride. (Original magniﬁcation of 200 in parts B and C.)
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30 fractions) at the site of purpura. Seven months after the addi-
tional radiotherapy, an easy-to-bleed red nodule developed on the
right external auditory meatus (Figure 2A), which histologically
revealed AS. Since the standard surgical therapy would be
impractical, we employed a CyberKnife and administered 17.5 mgsodium risedronate hydrate weekly, as we previously reported.6
The lesion was irradiated with 40 Gy in eight fractions. One
month after the irradiation, the tumor mass regressed completely
(Figure 2B). No severe side effect such as radiation dermatitis was
observed at the site of the irradiated lesion. We monitored local
recurrences of AS by regular physical examination (no purpura and
no dermal nodule) for the skin lesion, by magnetic resonance
imaging for the external auditory canal (every 3 months), and by
positron emission tomography for the systemic metastasis (every
½ years). No sign of local recurrence or systemic lesions was
observed for 1 year.Discussion
In this report, we describe a case of recurrent AS that metastasized
to the right external auditory meatus, which was treated success-
fully with CyberKnife and weekly administration of BP risedronate
sodium. AS is a highly aggressive type of vascular tumor, and it is
difﬁcult for dermatologists to control AS systemically, or even
locally, with standard treatment such as surgical resection or
radiation.1e3 Recently, Fujisawa et al7 reported that chemo-
radiotherapy with taxanewas superior to conventional surgery and
radiotherapy, which suggested the necessity of systemic therapy to
control AS after local treatment, such as radiotherapy and surgical
treatment.
As we previously reported, CyberKnife is useful to treat
various cutaneous malignancies such as Merkel cell carcinoma,
dermatoﬁbrosarcoma protuberance, and metastatic porocarci-
noma, even in inoperable cases.8,9,16 CyberKnife delivers extra-
cranial stereotactic radiotherapy with millimetric precision,
leading to disease control and toxicity proﬁles that are equal to or
better than those of other available therapies.10 Although areas
irradiated using conventional radiotherapy show local recurrence,
in the present case, AS could be controlled for 1 year using
CyberKnife, even the remote metastatic lesions. Our present case
suggested that CyberKnife is one of the optimal tools for the local
control of AS.
The use of BPs in malignancy has been increasing.11e13 A pre-
vious in vitro study revealed that the antitumor effect of BPs for
breast cancer cells was equal or even superior to that of doce-
taxel.13 In addition, as we previously reported, BPs modiﬁed the
production of chemokines from M2 macrophages, which might
modulate the tumor microenvironment optimally in the lesional
skin of AS.5 Moreover, another report also suggested the phar-
macological inhibition of MMP-9 by aminobisphosphonate, which
leads to the induction of antitumor immune responses by the
abrogation of immunosuppressive macrophages.14 MMP-9 is a
stromal factor that remodels the extracellular matrix, and pro-
motes sprouting and growth of new blood vessels by producing
vascular endothelial growth factor.15 Notably, as we previously
reported, about 80% of AS cases in our institute expressed MMP-9,6
and all cases of AS that clinically responded to BP expressed MMP-
9.6 In aggregate, these reports suggested that BP could be one of
the optimal supportive therapies to inhibit remote metastasis of
AS and tumor-induced angiogenesis by its immunomodulatory
effects.
In the present case, there was no sign of local recurrence or
systemic lesions for 1 year after the CyberKnife therapy in com-
bination with weekly administration of BPs. Our present study
might suggest the novel possibility of using CyberKnife with
weekly administration of BPs for the treatment of inoperable
metastatic AS.
Figure 2 Magnetic resonance imaging of T1-weighted image (A) before and (B) after irradiation with CyberKnife. The arrows show the tumor mass on the right external auditory
meatus.
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